Towards novel therapeutics for HIV through fragment-based screening and drug design

Progress in Biophysics and Molecular Biology

Volumn 116, Issue 2-3, 2014, Pages 124-140

  Tiefenbrunn, Theresa ^a   Stout, C David ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Allosteric sites; FBDD; Fragment based screening; HIV 1

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIRETROVIRUS AGENT; ENZYME INHIBITOR;

CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS; PHYSIOLOGY; PROCEDURES;

ANTI-RETROVIRAL AGENTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HIV;

EID: 84924059076     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2014.09.009     Document Type: Article

References (41)

1. Al-Mawsawi L.Q., Neamati N. Allosteric inhibitor development targeting HIV-1 integrase. ChemMedChem 2011, 6:228-241.
2. Ali A., Bandaranayake R.M., Cai Y., King N.M., Kolli M., Mittal S., Murzycki J.F., Nalam M.N., Nalivaika E.A., Ozen A., Prabu-Jeyabalan M.M., Thayer K., Schiffer C.A. Molecular basis for drug resistance in HIV-1 protease. Viruses 2011, 2:2509-2535.
3. Bauman J.D., Das K., Ho W.C., Baweja M., Himmel D.M., Clark A.D., Oren D.A., Boyer P.L., Hughes S.H., Shatkin A.J., Arnold E. Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design. Nucleic Acids Res. 2008, 36:5083-5092.
4. Bauman J.D., Patel D., Dharia C., Fromer M.W., Ahmed S., Frenkel Y., Vijayan R.S., Eck J.T., Ho W.C., Das K., Shatkin A.J., Arnold E. Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening. J.Med. Chem. 2013, 56:2738-2746.
5. Blaney J., Nienaber V., Burley S.K. Fragment-based Lead discovery and optimization using X-Ray crystallography, computational chemistry, and high-throughput organic synthesis. Fragment-based Approaches in Drug Discovery 2006, 215-248. Wiley-VCH Verlag GmbH & Co. KGaA.
6. Christ F., Voet A., Marchand A., Nicolet S., Desimmie B.A., Marchand D., Bardiot D.E., Van der Veken N.J., Van Remoortel B., Strelkov S.V., De Maeyer M., Chaltin P., Debyser Z. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat. Chem. Biol. 2010, 6:442-448.
7. Chu S.D., Gochin M. Identification of fragments targeting an alternative pocket on HIV-1 gp41 by NMR screening and similarity searching. Bioorg. Med. Chem. Lett. 2013, 23:5114-5118.
8. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D. Biol. Crystallogr. 1994, 50:760-763. Collaborative.
9. Dalvit C. NMR methods in fragment screening: theory and a comparison with other biophysical techniques. Drug Discov. Today 2009, 14:1051-1057.
10. Das K., Arnold E. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. Curr. Opin. Virol. 2013, 3:111-118.
11. Davidson A., Begley D.W., Lau C., Varani G. Asmall-molecule probe induces a conformation in HIV TAR RNA capable of binding drug-like fragments. J.Mol. Biol. 2011, 410:984-996.
12. De Clercq E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmacognosia 1999, 54:26-45.
13. De Luca L., Ferro S., Morreale F., Christ F., Debyser Z., Chimirri A., Gitto R. Fragment hopping approach directed at design of HIV IN-LEDGF/p75 interaction inhibitors. J.Enzyme Inhibit. Med. Chem. 2013, 28:1002-1009.
14. Debnath A.K. Rational design of HIV-1 entry inhibitors. Methods Mol. Biol. 2013, 993:185-204.
15. Engelman A., Kessl J.J., Kvaratskhelia M. Allosteric inhibition of HIV-1 integrase activity. Curr. Opin. Chem. Biol. 2013, 17:339-345.
16. Fenwick C.W., Tremblay S., Wardrop E., Bethell R., Coulomb R., Elston R., Faucher A.M., Mason S., Simoneau B., Tsantrizos Y., Yoakim C. Resistance studies with HIV-1 non-catalytic site integrase inhibitors. Antivir. Ther. 2011, 16. A9-A9.
17. Geitmann M., Elinder M., Seeger C., Brandt P., de Esch I.J., Danielson U.H. Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening. J.Med. Chem. 2011, 54:699-708.
18. Haqqani A.A., Tilton J.C. Entry inhibitors and their use in the treatment of HIV-1 infection. Antivir. Res. 2013, 98:158-170.
19. Krishnan L., Engelman A. Retroviral integrase proteins and HIV-1 DNA integration. J.Biol. Chem. 2012, 287:40858-40866.
20. Lee T., Laco G.S., Torbett B.E., Fox H.S., Lerner D.L., Elder J.H., Wong C.H. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV invitro and exvivo. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:939-944.
21. Lepre C.A. Practical aspects of NMR-based fragment screening. Methods Enzymol. 2011, 493:219-239.
22. Navratilova I., Besnard J., Hopkins A.L. Screening for GPCR ligands using surface plasmon resonance. ACS Med. Chem. Lett. 2011, 2:549-554.
23. Niesen F.H., Berglund H., Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2007, 2:2212-2221.
24. Organization W.H. HIV Resistance Report 2012.
25. Peat T.S., Rhodes D.I., Vandegraaff N., Le G., Smith J.A., Clark L.J., Jones E.D., Coates J.A., Thienthong N., Newman J., Dolezal O., Mulder R., Ryan J.H., Savage G.P., Francis C.L., Deadman J.J. Small molecule inhibitors of the LEDGF site of human immunodeficiency virus integrase identified by fragment screening and structure based design. PLoS One 2012, 7:e40147.
26. Perryman A.L., Lin J.H., McCammon J.A. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci. 2004, 13:1108-1123.
27. Perryman A.L., Zhang Q., Soutter H.H., Rosenfeld R., McRee D.E., Olson A.J., Elder J.E., Stout C.D. Fragment-based screen against HIV protease. Chem. Biol. Drug Des. 2010, 75:257-268.
28. Quashie P.K., Mesplede T., Wainberg M.A. HIV drug resistance and the advent of integrase inhibitors. Curr. Infect. Dis. Rep. 2013, 15:85-100.
29. Read R.J., Schierbeek A.J. Aphased translation function. J.Appl. Crystallogr. 1988, 21:490-495.
30. Rhodes D.I., Peat T.S., Vandegraaff N., Jeevarajah D., Le G., Jones E.D., Smith J.A., Coates J.A., Winfield L.J., Thienthong N., Newman J., Lucent D., Ryan J.H., Savage G.P., Francis C.L., Deadman J.J. Structural basis for a new mechanism of inhibition of HIV-1 integrase identified by fragment screening and structure-based design. Antivir. Chem. Chemother. 2011, 21:155-168.
31. Serrao E., Debnath B., Otake H., Kuang Y., Christ F., Debyser Z., Neamati N. Fragment-based discovery of 8-hydroxyquinoline inhibitors of the HIV-1 integrase-lens epithelium-derived growth factor/p75 (IN-LEDGF/p75) interaction. J.Med. Chem. 2013, 56:2311-2322.
32. Shen L., Peterson S., Sedaghat A.R., McMahon M.A., Callender M., Zhang H., Zhou Y., Pitt E., Anderson K.S., Acosta E.P., Siliciano R.F. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 2008, 14:762-766.
33. Sundquist W.I., Krausslich H.G. HIV-1 assembly, budding, and maturation. Cold Spring Harb. Perspect. Med. 2012, 2:a006924.
34. Teixeira C., Gomes J.R., Gomes P., Maurel F., Barbault F. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug. Eur. J. Med. Chem. 2011, 46:979-992.
35. Tiefenbrunn T., Forli S., Baksh M.M., Chang M.W., Happer M., Lin Y.-C., Perryman A.L., Rhee J.-K., Torbett B.E., Olson A.J., Elder J.H., Finn M.G., Stout C.D. Small molecule regulation of protein conformation by binding in the flap of HIV protease. ACS Chem. Biol. 2013, 8:1223-1231.
36. Tiefenbrunn T., Forli S., Happer M., Gonzalez A., Tsai Y., Soltis M., Elder J.H., Olson A.J., Stout C.D. Crystallographic fragment-based drug discovery: use of a brominated fragment library targeting HIV protease. Chem. Biol. Drug Des. 2014, 83:141-148.
37. Wensing A.M., van Maarseveen N.M., Nijhuis M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antivir. Res. 2009, 85:59-74.
38. Wheeler W.H., Ziebell R.A., Zabina H., Pieniazek D., Prejean J., Bodnar U.R., Mahle K.C., Heneine W., Johnson J.A., Hall H.I. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010, 24:1203-1212.
39. Wielens J., Headey S.J., Deadman J.J., Rhodes D.I., Le G.T., Parker M.W., Chalmers D.K., Scanlon M.J. Fragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus 1. ChemMedChem 2011, 6:258-261.
40. Wielens J., Headey S.J., Rhodes D.I., Mulder R.J., Dolezal O., Deadman J.J., Newman J., Chalmers D.K., Parker M.W., Peat T.S., Scanlon M.J. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification?. J.Biomol. Screen 2013, 18:147-159.
41. Yu F., Lu L., Du L., Zhu X., Debnath A.K., Jiang S. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket. Viruses 2013, 5:127-149.